Literature DB >> 26964769

Commentary on "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer." Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38.

Ganesh S Palapattu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26964769     DOI： 10.1016/j.urolonc.2015.12.011

Source DB:  PubMed          Journal:  Urol Oncol        ISSN： 1078-1439            Impact factor:   3.498


× No keyword cloud information.
  118 in total

Review 1.  Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Joshua M Lang; Robert B Den; Isla P Garraway; Tamara L Lotan; Ashley E Ross; Tanya Stoyanova; Steve Y Cho; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2015-10-19       Impact factor: 4.104

Review 2.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

3.  Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.

Authors:  Puranik Purushottamachar; Andrew K Kwegyir-Afful; Marlena S Martin; Vidya P Ramamurthy; Senthilmurugan Ramalingam; Vincent C O Njar
Journal:  ACS Med Chem Lett       Date:  2016-05-23       Impact factor: 4.345

Review 4.  Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.

Authors:  Joshua M Jackson; Małgorzata A Witek; Joyce W Kamande; Steven A Soper
Journal:  Chem Soc Rev       Date:  2017-07-17       Impact factor: 54.564

5.  Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.

Authors:  Chenchen He; Shaofeng Duan; Liang Dong; Yifen Wang; Qingting Hu; Chunjing Liu; Marcus L Forrest; Jeffrey M Holzbeierlein; Suxia Han; Benyi Li
Journal:  Prostate       Date:  2017-06-20       Impact factor: 4.104

6.  Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.

Authors:  Sumit Isharwal; Shrey Modi; Nivedita Arora; Charles Uhlrich; Bhuwan Giri; Usman Barlass; Ayman Soubra; Rohit Chugh; Scott M Dehm; Vikas Dudeja; Ashok Saluja; Sulagna Banerjee; Badrinath Konety
Journal:  Prostate       Date:  2017-02-01       Impact factor: 4.104

7.  Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.

Authors:  Bin Wang; U-Ging Lo; Kaijie Wu; Payal Kapur; Xiangyang Liu; Jun Huang; Wei Chen; Elizabeth Hernandez; John Santoyo; Shi-Hong Ma; Rey-Chen Pong; Dalin He; Yi-Qiang Cheng; Jer-Tsong Hsieh
Journal:  Int J Cancer       Date:  2017-07-31       Impact factor: 7.396

Review 8.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 9.  NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.

Authors:  Yu Jen Jan; Jie-Fu Chen; Yazhen Zhu; Yi-Tsung Lu; Szu Hao Chen; Howard Chung; Matthew Smalley; Yen-Wen Huang; Jiantong Dong; Li-Ching Chen; Hsiao-Hua Yu; James S Tomlinson; Shuang Hou; Vatche G Agopian; Edwin M Posadas; Hsian-Rong Tseng
Journal:  Adv Drug Deliv Rev       Date:  2018-03-15       Impact factor: 15.470

10.  NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.

Authors:  David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Robert J Matusik; Ren J Jin; Simon W Hayward
Journal:  Prostate       Date:  2016-05-16       Impact factor: 4.104
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.